TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31468656

Group type: EXPERIMENTAL
Intervention: Xbox KinectTM games training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy older adults)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (PD patients)
Number of subjects: 16
Study: 30607757

Group type: EXPERIMENTAL
Intervention: Culturally-adapted Cognitive Processing Therapy (CPT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 73
Study: 27902945

Group type: EXPERIMENTAL
Intervention: Artificial cervical disc replacement (ACDR) with Prestige-LP prosthesis
Number of subjects: 25
Study: 26432120

Group type: EXPERIMENTAL
Intervention: Trifocal IOLs (Finevision Micro F)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bifocal IOLs (Acrysof IQ Restor +3.0)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of trifocal vs bifocal IOLs
Number of subjects: 28
Study: 23435303

Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (PIP) - home visits by community health workers (CHWs) in addition to standard care
Number of subjects: 644

Group type: COMPARATOR
Intervention: Standard care - comprehensive healthcare at clinics
Number of subjects: 644
Study: 21421179

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg/d
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg/d
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg/d
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses combined)
Number of subjects: 314
Study: 19183976

Group type: EXPERIMENTAL
Intervention: Stented group (stent placed)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no stent placed)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Group 1 (no stent, no marked ureteral edema)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Group 2 (stent placed, with marked ureteral edema)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Group 3 (stent placed, with polypoid change)
Number of subjects: 228
Study: 18235907

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10.0% phenylephrine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of 10.0% phenylephrine vs 2.5% phenylephrine
Number of subjects: 28
Study: 15126920

Group type: EXPERIMENTAL
Intervention: Oral methionine (100 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamins C (1g/day) and E (800 mg/day) for 8 consecutive days
Number of subjects: 12
Study: 11790365

Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a pharmacist 2 days after discharge
Number of subjects: 221

Group type: COMPARATOR
Intervention: No phone call (control group)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a pharmacist
Number of subjects: 221
Study: 9813511

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms kg‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7632128

Group type: EXPERIMENTAL
Intervention: Serum IGF‐1 concentrations in patients with postpolio syndrome
Number of subjects: 87

Group type: COMPARATOR
Intervention: Reference population comprising 392 randomly selected individuals
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Correlation analysis of IGF‐1 concentrations
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GH substitution treatment
Number of subjects: 87
Study: 2198350

Group type: EXPERIMENTAL
Intervention: Nipple stimulation with a breast pump
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nipple stimulation with a breast pump (failed responders switched to oxytocin)
Number of subjects: 0
Study: 332439

Group type: EXPERIMENTAL
Intervention: 26 mg EACH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 6 mg EACH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 33 mg EACH
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31125266

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (PemCis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy with etoposide-cisplatin (EtoCis)
Number of subjects: 0
Study: 27577536

Group type: EXPERIMENTAL
Intervention: OtoTrain (web-based otoscopy simulator)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard otology lectures (Control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of post-test scores
Number of subjects: 41
Study: 25771237

Group type: EXPERIMENTAL
Intervention: Posterior left atrial isolation (PLAI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Wide antral isolation (WAI)
Number of subjects: 220
Study: 23207373

Group type: EXPERIMENTAL
Intervention: 30 mg oral controlled‐release morphine
Number of subjects: 10
Study: 21208413

Group type: EXPERIMENTAL
Intervention: Training course for insurance physicians on applying guidelines for depression
Number of subjects: 0
Study: 19201775

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg/40 mg at weeks 0/2, then 40 mg every other week or weekly to week 56)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Adalimumab (open-label extension after week 56)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 16621339

Group type: EXPERIMENTAL
Intervention: Sertraline plus CM
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Sertraline-only
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo plus CM
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo-only
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Sertraline conditions
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: CM conditions
Number of subjects: 229
Study: 12821553

Group type: EXPERIMENTAL
Intervention: Postintervention IVUS
Number of subjects: 7484

Group type: COMPARATOR
Intervention: Preprocedural lesion characteristics
Number of subjects: 7484
Study: 10475180

Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous, twice daily for 3 months)
Number of subjects: 2267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2267

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 2267
Study: 8693440

Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulphate 1 mg/ml (5 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (5 ml)
Number of subjects: 10
Study: 1867418

Group type: EXPERIMENTAL
Intervention: Awake extubation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Anesthetized extubation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 6226946

Group type: EXPERIMENTAL
Intervention: One-Day Hospital (ODH)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Several-Day Hospital Care (SHC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both ODH and SHC
Number of subjects: 121
Study: 4020081

Group type: EXPERIMENTAL
Intervention: Crohn's disease with malnutrition
Number of subjects: 7

Group type: COMPARATOR
Intervention: Crohn's disease without growth disturbances
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All Crohn's disease patients
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Patients with delayed gastric emptying
Number of subjects: 7
Study: 30789463

Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 176
Study: 29747047

Group type: EXPERIMENTAL
Intervention: Brief exercise and diet advice provided during orthodontic visits
Number of subjects: 0
Study: 26886857

Group type: EXPERIMENTAL
Intervention: Stratified cluster sampling under randomized response models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classic sampling theories and total probability formulas
Number of subjects: 0
Study: 24090685

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet with soluble milk proteins (PRO)
Number of subjects: 4
Study: 22729386

Group type: EXPERIMENTAL
Intervention: Sample sizes of a minimum of 20 for reliability
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Sample sizes of a minimum of 80 for validity
Number of subjects: 713
Study: 20063907

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent systems for monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research and case studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 18689559

Group type: EXPERIMENTAL
Intervention: 700 IU/day of supplemental vitamin D(3) and 500 mg/day of supplemental calcium
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 15974900

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg; two 40 mg tablets once daily)
Number of subjects: 98
Study: 12873069

Group type: EXPERIMENTAL
Intervention: Teaching Kids to Cope (TKC) program
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study: 10673791

Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8738693

Group type: EXPERIMENTAL
Intervention: Head-down tilt position (HDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study: 1761666

Group type: EXPERIMENTAL
Intervention: IVF treatment with human menopausal gonadotrophin (HMG)
Number of subjects: 599

Group type: COMPARATOR
Intervention: OHSS cases
Number of subjects: 599
Study: 6121736

Group type: EXPERIMENTAL
Intervention: Solpadeine
Number of subjects: 74

Group type: COMPARATOR
Intervention: DNP
Number of subjects: 74
Study: 30859428

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Non-antibiotic treatment
Number of subjects: 109
Study: 29607625

Group type: EXPERIMENTAL
Intervention: Turmeric tonic, administered twice a day for 9 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, administered twice a day for 9 weeks
Number of subjects: 40
Study: 26780988

Group type: EXPERIMENTAL
Intervention: Moti-4 intervention
Number of subjects: 131
Study: 25571684

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum DN‐173 010 (1 x 10(10) cfu/g) in probiotic fruit yogurt, 110 g per day for 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo fruit yogurt, 110 g per day for 2 weeks
Number of subjects: 52
Study: 22809258

Group type: COMPARATOR
Intervention: Continuous exercise training (CON)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intermittent exercise training (INT)
Number of subjects: 23
Study: 19358061

Group type: EXPERIMENTAL
Intervention: Conventional 24-hour pH-monitoring
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wireless 48-hour Bravo pH-monitoring
Number of subjects: 76
Study: 17439889

Group type: EXPERIMENTAL
Intervention: tight‐cuff cooling‐garment prototype for peripheral cooling
Number of subjects: 20

Group type: COMPARATOR
Intervention: sham condition
Number of subjects: 20
Study: 16680620

Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) + paid work therapy (WT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Paid work therapy (WT)
Number of subjects: 145
Study: 11940541

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.0 mg/kg subcutaneously every 12 hours +/- initial 30 mg intravenous bolus)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.3 to 0.75 mg/kg subcutaneously every 12 hours +/- initial intravenous bolus of 30 mg)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (bolus 60 U/kg; infusion 12 U/kg per hour)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (bolus 40 U/kg; infusion 7 U/kg per hour)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 483

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 483
Study: 10340157

Group type: EXPERIMENTAL
Intervention: Immediate-quit group with 31-day contingency ($300 compensation for abstinence)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delayed-quit group with 2-day contingency ($300 compensation for abstinence)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Contingency duration (31 vs. 2 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Higher trait neuroticism, depression, and psychopathic deviate scores
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prequit cotinine concentrations and Fagerström Tolerance Questionnaire scores
Number of subjects: 56
Study: 8953400

Group type: EXPERIMENTAL
Intervention: Amiodarone (effective by electrophysiologic study)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amiodarone (ineffective by electrophysiologic study)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amiodarone (effective by Holter monitoring)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amiodarone (ineffective by Holter monitoring)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Group I (effective by both tests)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Group II (effective by either test)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Group III (ineffective by both tests)
Number of subjects: 31
Study: 1914378

Group type: EXPERIMENTAL
Intervention: 5 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg single oral dose of galanthamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: In vitro and ex vivo concentration responses
Number of subjects: 8
Study: 6140230

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol (beta‐1‐selective blockade)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 mg bupranolol (nonselective beta‐blockade)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both beta-blockers (metoprolol and bupranolol)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control, metoprolol, and bupranolol
Number of subjects: 14
Study: 29921318

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks
Number of subjects: 369

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 369
Study: 26299550

Group type: EXPERIMENTAL
Intervention: Midazolam (2.5 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil combination (1 mg midazolam and 5 μg/kg alfentanil)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg intravenous bolus)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 25030782

Group type: EXPERIMENTAL
Intervention: High-fructose (HF) sweetened beverage (710 mL/d, 50 g fructose/d, 15 g glucose/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-glucose (HG) sweetened beverage (710 mL/d, 50 g glucose/d, 15 g fructose/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-fructose (HF) sweetened beverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-glucose (HG) sweetened beverage
Number of subjects: 40
Study: 22591948

Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection
Number of subjects: 701

Group type: COMPARATOR
Intervention: Mesorectal excision alone
Number of subjects: 701
Study: 20033075

Group type: EXPERIMENTAL
Intervention: Aliskiren 150-300 mg per day
Number of subjects: 901

Group type: COMPARATOR
Intervention: Ramipril 5-10 mg per day
Number of subjects: 901
Study: 18005484

Group type: EXPERIMENTAL
Intervention: High-fibre meal (HFM) (15 g of fibre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre meal (LFM) (3 g of fibre)
Number of subjects: 10
Study: 16125961

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endostapler
Number of subjects: 40
Study: 12385542

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg orally once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg orally once daily with propranolol 40 mg orally twice daily
Number of subjects: 20
Study: 9465842

Group type: EXPERIMENTAL
Intervention: 5 mg nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 ng/kg/min ET-1
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4 ng/kg/min ET-1
Number of subjects: 12
Study: 7710436

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norverapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil and Norverapamil
Number of subjects: 0
Study: 2696627

Group type: EXPERIMENTAL
Intervention: Virgin silk 8-0 suture
Number of subjects: 206

Group type: COMPARATOR
Intervention: Interrupted nylon 9-0 suture
Number of subjects: 206

Group type: COMPARATOR
Intervention: Double running nylon 9-0 suture
Number of subjects: 206
Study: 181978

Group type: EXPERIMENTAL
Intervention: Exercise training with dietary control by dietitian counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise training without dietary control
Number of subjects: 60
Study: 31200043

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 43
Study: 28007005

Group type: EXPERIMENTAL
Intervention: 0.01% oral capsaicin gel
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.025% oral capsaicin gel
Number of subjects: 22
Study: 26093936

Group type: EXPERIMENTAL
Intervention: Whole slide images and virtual microscopy adaptive tutorials
Number of subjects: 43

Group type: COMPARATOR
Intervention: Traditional glass slide and textbook methods
Number of subjects: 43
Study: 23282331

Group type: EXPERIMENTAL
Intervention: Malevolent beliefs about voices
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Benevolent beliefs about voices
Number of subjects: 31

Group type: COMPARATOR
Intervention: General psychiatric symptoms
Number of subjects: 31

Group type: COMPARATOR
Intervention: Frequency of voices
Number of subjects: 31

Group type: COMPARATOR
Intervention: Perceived control of voices
Number of subjects: 31

Group type: COMPARATOR
Intervention: Levels of depression (BDI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Levels of anxiety (BAI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Severity of overall psychiatric symptoms (BPRS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Severity of negative symptoms (SANS)
Number of subjects: 31
Study: 21489699

Group type: EXPERIMENTAL
Intervention: 1 μg/kg CRH infusion
Number of subjects: 68
Study: 19407292

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 20 ml 0.5% bupivacaine (group 1)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Portal infiltration of 20 ml 0.5% bupivacaine (group 2)
Number of subjects: 137
Study: 16996359

Group type: EXPERIMENTAL
Intervention: Endoscope holder-assisted PEG placement (40 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional pull method of PEG (40 patients)
Number of subjects: 80
Study: 12518376

Group type: EXPERIMENTAL
Intervention: L-asparaginase therapy
Number of subjects: 60
Study: 11063156

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 9067278

Group type: EXPERIMENTAL
Intervention: Homozygous mutation (677C‐‐>T)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Plasma folate deficiency (<3 ng/ml)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Adequate folate levels with homozygous mutation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Homozygous mutation with little or no alcohol
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Homozygous mutation with moderate alcohol intake
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Homozygous normal genotype with 1 or more drinks/day
Number of subjects: 202
Study: 7933504

Group type: EXPERIMENTAL
Intervention: Buprenorphine suppository (0.4 mg) preoperative administration (group A1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine suppository (0.4 mg) postoperative administration (group A2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 0.1 mg of buprenorphine during surgery and postoperative administration of buprenorphine suppository (group A3)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 57
Study: 3286537

Group type: EXPERIMENTAL
Intervention: Cefamandole (2 days)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Cephazolin (5 days)
Number of subjects: 965
Study: 30180186

Group type: EXPERIMENTAL
Intervention: Integrated mobile health and behavioral intervention to enhance the capacity of ORWs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tools and training for ORWs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Motivation through periodic feedback
Number of subjects: 60
Study: 28169080

Group type: EXPERIMENTAL
Intervention: music group (n=60) receiving their favorite songs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: massage group (n=60) receiving Swedish massage
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: music-plus-massage group (n=60) receiving a combination of their favorite songs and Swedish massage
Number of subjects: 240

Group type: COMPARATOR
Intervention: control (n=60) receiving the conventional primary care
Number of subjects: 240
Study: 25919687

Group type: EXPERIMENTAL
Intervention: Active 'VL' TMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 30
Study: 23522308

Group type: EXPERIMENTAL
Intervention: Bronchoscopy-guided percutaneous tracheostomy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 51
Study: 21909151

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Pethidine 7.5mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine + Saline
Number of subjects: 50
Study: 19393768

Group type: EXPERIMENTAL
Intervention: PPA administration with educational module
Number of subjects: 190

Group type: COMPARATOR
Intervention: Initial explanation and baseline PPA administration
Number of subjects: 190